Assembling evidence grade
Loading
Independent evidence before payment.
Dual GIP/GLP-1 receptor agonist · also: Mounjaro, Zepbound, GIP/GLP-1
Tirzepatide carries an Evidence Grade of A (High confidence). The strongest published evidence catalogued is human rct / review.
Grade A rule: Two or more confirmatory human RCTs (an approved product, or completed Phase 3).
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Tirzepatide is a dual GIP and GLP-1 receptor agonist evaluated in the SURMOUNT and SURPASS randomised programmes. It is among the most rigorously studied compounds in this index, with approved branded formulations.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 6 randomised human trials here — the strongest kind of evidence. That is about the research, not about any particular seller or batch.
Strongest: randomised or pooled human trials.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024.
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England journal of medicine, 2024.
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 2022.
Tirzepatide: A Systematic Update. International journal of molecular sciences, 2022.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London, England), 2021.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England journal of medicine, 2021.
Observational, open-label or small human studies.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine, 2025.
Preclinical animal models — not a human outcome.
none catalogued
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Tirzepatide for overweight and obesity management. Expert opinion on pharmacotherapy, 2025.
Tirzepatide: A Review in Type 2 Diabetes. Drugs, 2024.
Tirzepatide (Mounjaro®, Zepbound®). PubMed, 2024.
New Drug: Tirzepatide (Mounjaro(™)). The Senior care pharmacist, 2023.
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 2020.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Evidence applies to approved branded product and supervised use. Unbranded material is not the studied substance and carries no transfer of those findings.
An approved prescription-only medicine. Buying it without a prescription bypasses medical supervision and the approved supply chain — a vendor selling it as “research use only” is offering a prescription drug with no prescription and no clinical oversight.
PepCred flags any vendor selling this compound without requiring a prescription as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Sample of 8 (not ranked) — see all on ClinicalTrials.gov:
The molecule is FDA-approved (US) as a branded medicine (Mounjaro, Mounjaro KwikPen, Zepbound, Zepbound KwikPen). The unbranded, research-grade material sold as Tirzepatide is a different, unapproved product of unverified identity, purity and concentration.
Reporting volume (not a safety rate): 160,663 adverse-event reports name this ingredient in the FDA FAERS database. FAERS reports are voluntary and unverified, are not a rate, and do not establish that the drug caused the event — high counts usually track high prescribing volume.
PepCred note: Approved branded formulations (FDA, MHRA) for stated indications.
Tirzepatide is a prescription-only medicine. The lawful way to get it is a GPhC-registered pharmacy that requires a prescription — never a grey-market seller.
An ingredient-name listing is not the licensed branded medicine. These unranked records are shown to expose prescription bypass and other risks, not to suggest where to buy.
None of these is verified for human use.